Introduction
Methods
Statistical analysis
Results
Characteristic | Invasive breast cancer (n = 36,050) | Lobular (n = 5135) | Ductal (n = 28,590) | |||
---|---|---|---|---|---|---|
No MRI (%) | MRI (%) | No MRI (%) | MRI (%) | No MRI (%) | MRI (%) | |
Year of incidence | ||||||
2011 | 8455 (70.4) | 3559 (29.6) | 842 (48.6) | 890 (51.4) | 7044 (73.9) | 2487 (26.1) |
2012 | 8586 (70.7) | 3558 (29.3) | 794 (46.1) | 928 (53.9) | 7159 (74.3) | 2472 (25.7) |
2013 | 8269 (69.5) | 3623 (30.5) | 725 (43.1) | 956 (56.9) | 6925 (73.5) | 2503 (26.5) |
Age group (years) | ||||||
<50 | 3495 (51.6) | 3282 (48.4) | 246 (31.5) | 535 (68.5) | 3046 (54.1) | 2590 (45.9) |
50–70 | 13,974 (69.9) | 6023 (30.1) | 1168 (41.0) | 1683 (59.0) | 11,929 (74.6) | 4068 (25.4) |
70+ | 7814 (84.5) | 1,435 (15.5) | 947 (63.0) | 556 (37.0) | 6153 (88.4) | 804 (11.6) |
cT stage | ||||||
cT1 | 17,156 (73.4) | 6,211 (26.6) | 1407 (49.9) | 1413 (50.1) | 14,663 (76.6) | 4489 (23.4) |
cT2 | 6164 (62.9) | 3630 (37.1) | 657 (38.7) | 1042 (61.3) | 5036 (67.3) | 2443 (32.7) |
cT3 | 377 (43.8) | 484 (56.2) | 97 (30.6) | 220 (69.4) | 236 (49.1) | 245 (50.9) |
cT4 | 158 (75.2) | 52 (24.8) | 17 (56.7) | 13 (43.3) | 128 (78.5) | 35 (21.5) |
Unknown | 1455 (80.0) | 363 (20.0) | 183 (68.0) | 86 (32.0) | 1065 (81.0) | 250 (19.0) |
cN stage | ||||||
cN0 | 22,393 (70.6) | 9316 (29.4) | 2091 (45.8) | 2473 (54.2) | 18,692 (74.5) | 6383 (25.5) |
cN1–3 | 2575 (66.3) | 1312 (33.8) | 235 (46.6) | 269 (53.4) | 2236 (69.1) | 1002 (30.9) |
Unknown | 342 (75.3) | 112 (24.7) | 35 (52.2) | 32 (47.8) | 200 (72.2) | 77 (27.8) |
ER/PR/HER2 status | ||||||
ER+ or PR+, and HER2− | 18,690 (69.3) | 8276 (30.7) | 2011 (44.0) | 2564 (56.0) | 15,468 (74.3) | 5356 (25.7) |
ER+ or PR+, and HER2+ | 1829 (67.3) | 890 (32.7) | 95 (48.2) | 102 (51.8) | 1660 (68.3) | 769 (31.7) |
ER− and PR− and HER2− | 2692 (74.2) | 934 (25.8) | 70 (64.2) | 39 (35.8) | 2356 (74.2) | 818 (25.8) |
ER− and PR− and HER2+ | 862 (68.5) | 397 (31.5) | 12 (41.4) | 17 (58.6) | 791 (69.3) | 350 (30.7) |
Unknown | 1237 (83.6) | 243 (16.4) | 173 (76.9) | 52 (23.1) | 853 (83.5) | 169 (16.5) |
Grade | ||||||
1 | 6510 (72.5) | 2476 (27.6) | 368 (42.5) | 498 (57.5) | 5366 (75.1) | 1779 (24.9) |
2 | 10,777 (68.1) | 5040 (31.9) | 1591 (45.8) | 1886 (54.2) | 8720 (74.3) | 3024 (25.7) |
3 | 7016 (71.7) | 2771 (28.3) | 256 (50.9) | 247 (49.1) | 6,351 (72.7) | 2385 (27.3) |
Unknown | 1007 (69.0) | 453 (31.0) | 146 (50.5) | 143 (49.5) | 691 (71.6) | 274 (28.4) |
Multifocality | ||||||
No | 22,150 (73.5) | 8008 (26.5) | 1854 (48.6) | 1964 (51.4) | 18,764 (76.8) | 5656 (23.2) |
Yes | 2738 (50.5) | 2688 (49.5) | 453 (36.3) | 796 (63.7) | 2102 (54.2) | 1777 (45.8) |
Unknown | 422 (90.6) | 44 (9.4) | 54 (79.4) | 14 (20.6) | 262 (90.0) | 29 (10.0) |
Margin involvement | ||||||
Yes | 981 (69.4) | 433 (30.6) | 156 (53.2) | 137 (46.8) | 755 (73.8) | 268 (26.2) |
No | 23,474 (69.8) | 10,166 (30.2) | 2059 (44.3) | 2592 (55.7) | 19,753 (73.5) | 7106 (26.5) |
Contralateral breast cancer | ||||||
Yes | 336 (45.7) | 399 (54.3) | 52 (32.3) | 109 (67.7) | 256 (48.7) | 270 (51.3) |
No | 24,974 (70.7) | 10,341 (96.3) | 2309 (46.4) | 2665 (53.6) | 20,872 (74.4) | 7192 (25.6) |
Outcome characteristic | MRI use | Primary mastectomy | Margin involvement (more than focal) | Secondary mastectomy | Contralateral breast cancer | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OR | 95% CI |
P
| OR | 95% CI |
P
| OR | 95% CI |
P
| OR | 95% CI |
P
| OR | 95% CI |
P
| |
MRI | |||||||||||||||
No | N/A | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
Yes | 1.22 | 1.15–1.29 | <0001 | 0.84 | 0.73–0.97 | 0.015 | 1.07 | 0.89–1.29 | 0.434 | 3.55 | 3.01–4.17 | <.0001 | |||
Year of incidence | |||||||||||||||
2011 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
2012 | 1.02 | 0.96–1.09 | 0.468 | 0.94 | 0.88–0.99 | 0.025 | 0.84 | 0.73–0.96 | 0.011 | 0.79 | 0.65–0.95 | 0.012 | 1.05 | 0.87–1.26 | 0.636 |
2013 | 1.11 | 1.04–1.18 | 0.001 | 0.93 | 0.88–0.99 | 0.020 | 0.73 | 0.63–0.84 | <.0001 | 0.80 | 0.66–0.97 | 0.026 | 1.18 | 0.98–1.41 | 0.081 |
Age group (years) | |||||||||||||||
70+ | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
<50 | 6.38 | 5.89–6.91 | <.0001 | 0.65 | 0.60–0.70 | <.0001 | 1.33 | 1.11–1.60 | 0.002 | 1.99 | 1.56–2.54 | <.0001 | 0.56 | 0.44–0.71 | <.0001 |
50–69 | 2.84 | 2.65–3.04 | <.0001 | 0.46 | 0.44–0.49 | <.0001 | 0.86 | 0.74–0.99 | 0.041 | 1.02 | 0.83–1.26 | 0.848 | 0.65 | 0.54–0.77 | <.0001 |
Histology | |||||||||||||||
Ductal | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
Lobular | 3.48 | 3.25–3.73 | <.0001 | 1.55 | 1.45–1.67 | <.0001 | 1.94 | 1.64–2.28 | <.0001 | 2.55 | 2.06–3.14 | <.0001 | 1.15 | 0.94–1.39 | 0.168 |
Other | 0.88 | 0.78–0.99 | 0.026 | 1.01 | 0.90–1.12 | 0.920 | 1.41 | 1.11–1.80 | 0.005 | 1.12 | 0.79–1.59 | 0.529 | 0.95 | 0.69–1.31 | 0.754 |
Clinical tumor size (cT) | |||||||||||||||
cT1 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
cT2 | 1.66 | 1.57–1.76 | <.0001 | 3.17 | 3.00–3.35 | <.0001 | 1.49 | 1.29–1.71 | <.0001 | 1.40 | 1.17–1.69 | <.0001 | 0.57 | 0.46–0.70 | <.0001 |
cT3–4 | 2.82 | 2.44–3.25 | <.0001 | 34.67 | 26.08–46.09 | <.0001 | 3.21 | 1.55–6.66 | 0.002 | 2.19 | 0.78–6.16 | 0.139 | 0.51 | 0.30–0.89 | 0.017 |
Unknown | 0.66 | 0.57–0.75 | <.0001 | 2.34 | 2.09–2.62 | <.0001 | 2.42 | 1.91–3.07 | <.0001 | 2.63 | 1.93–3.59 | <.0001 | 2.23 | 1.72–2.88 | <.0001 |
Clinical nodal status (cN) | |||||||||||||||
cN0 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
cN1–3 | 0.94 | 0.87–1.02 | 0.131 | 2.53 | 2.33–2.75 | <.0001 | 1.50 | 1.21–1.84 | 0.0001 | 1.50 | 1.14–1.98 | 0.004 | 0.81 | 0.59–1.11 | 0.189 |
Unknown | 1.00 | 0.78–1.28 | 0.984 | 1.42 | 1.13–1.79 | 0.003 | 1.60 | 0.98–2.64 | 0.063 | 1.86 | 0.97–3.54 | 0.061 | 0.82 | 0.40–1.70 | 0.599 |
ER, PR and HER2 status | |||||||||||||||
ER+ or PR+, and HER2− | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
ER+ or PR+, and HER2+ | 1.03 | 0.93–1.13 | 0.595 | 1.17 | 1.07–1.29 | 0.001 | 1.30 | 1.05–1.59 | 0.014 | 1.31 | 1.00–1.74 | 0.055 | 0.97 | 0.69–1.36 | 0.853 |
ER− and PR− and HER2− | 0.90 | 0.82–0.99 | 0.023 | 1.08 | 0.99–1.18 | 0.095 | 0.71 | 0.56–0.90 | 0.004 | 1.15 | 0.86–1.54 | 0.356 | 0.81 | 0.55–1.20 | 0.291 |
ER− and PR− and HER2+ | 1.11 | 0.97–1.27 | 0.148 | 1.56 | 1.36–1.79 | <.0001 | 1.20 | 0.86–1.66 | 0.279 | 1.95 | 1.30–2.93 | 0.001 | 0.56 | 0.27 –1.14 | 0.110 |
Unknown | 0.71 | 0.60–0.85 | 0.0001 | 1.18 | 1.03–1.36 | 0.021 | 0.86 | 0.61–1.22 | 0.398 | 1.41 | 0.91–2.18 | 0.122 | 2.33 | 1.72–3.14 | <.0001 |
Tumor grade | |||||||||||||||
1 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
2 | 0.91 | 0.86–0.97 | 0.005 | 1.23 | 1.15–1.31 | <.0001 | 1.48 | 1.26–1.73 | <.0001 | 1.59 | 1.27–1.99 | <.0001 | 0.71 | 0.60–0.84 | <.0001 |
3 | 0.79 | 0.73–0.85 | <.0001 | 1.18 | 1.09–1.28 | <.0001 | 1.63 | 1.35–1.97 | <.0001 | 1.87 | 1.44–2.43 | <.0001 | 0.35 | 0.26–0.47 | <.0001 |
Unknown | 1.06 | 0.92–1.22 | 0.409 | 1.30 | 1.13–1.48 | <.0001 | 1.98 | 1.48–2.65 | <.0001 | 1.41 | 0.93–2.14 | 0.110 | 0.86 | 0.62–1.19 | 0.354 |
Multifocality | |||||||||||||||
No | 1 (ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||
Yes | 2.35 | 2.20–2.50 | <.0001 | 4.44 | 4.15–4.76 | <.0001 | 2.85 | 2.44–3.34 | <.0001 | 4.78 | 3.92–5.82 | <.0001 | 1.02 | 0.84–1.25 | 0.831 |
Unknown | 0.39 | 0.27–0.55 | <.0001 | 1.48 | 1.16–1.90 | 0.002 | 3.46 | 1.63–7.35 | 0.001 | 3.89 | 1.42–10.6 | 0.008 | 0.87 | 0.45–1.71 | 0.688 |
Margin involvement | |||||||||||||||
No | 1 (Ref) | ||||||||||||||
Yes | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 41.94 | 35.68–49.30 | <0.001 | N/A | N/A | N/A |
Primary mastectomies
Outcome characteristic | MRI use | Primary mastectomy | Margin involvement (more than focal) | Secondary mastectomy | Contralateral breast cancer | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OR | 95% CI |
P
| OR | 95% CI |
P
| OR | 95% CI |
P
| OR | 95% CI |
P
| OR | 95% CI |
P
| |
MRI | |||||||||||||||
No | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||||||||||||
Yes | N/A | 1.30 | 1.22–1.39 | <.0001 | 0.90 | 0.77–1.06 | 0.202 | 1.23 | 1.00–1.53 | 0.054 | 4.07 | 3.38–4.90 | <.0001 | ||
Year of incidence | |||||||||||||||
2011 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
2012 | 1.02 | 0.95–1.09 | 0.629 | 0.93 | 0.87–0.99 | 0.025 | 0.83 | 0.71–0.98 | 0.025 | 0.84 | 0.67–1.05 | 0.122 | 0.95 | 0.76–1.18 | 0.635 |
2013 | 1.08 | 1.01–1.16 | 0.029 | 0.93 | 0.87–1.00 | 0.047 | 0.75 | 0.64–0.89 | 0.001 | 0.90 | 0.72–1.13 | 0.363 | 1.14 | 0.92–1.40 | 0.242 |
Age group (years) | |||||||||||||||
70+ | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
<50 | 6.89 | 6.27–7.56 | <.0001 | 0.63 | 0.58–0.68 | <.0001 | 1.29 | 1.05–1.59 | 0.014 | 1.94 | 1.45–2.58 | <.0001 | 0.47 | 0.35–0.63 | <.0001 |
50−69 | 2.94 | 2.70–3.19 | <.0001 | 0.46 | 0.43–0.49 | <.0001 | 0.82 | 0.69–0.98 | 0.027 | 0.97 | 0.75–1.25 | 0.819 | 0.64 | 0.52–0.79 | <.0001 |
Clinical tumor size (cT) | |||||||||||||||
cT1 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
cT2 | 1.66 | 1.56–1.77 | <.0001 | 3.10 | 2.87–3.25 | <.0001 | 1.42 | 1.21–1.68 | <.0001 | 1.29 | 1.04–1.61 | 0.023 | 0.63 | 0.49–0.81 | <.001 |
cT3–4 | 3.08 | 2.57–3.69 | <.0001 | 36.35 | 25.30–52.23 | <.0001 | 3.61 | 1.36–9.60 | 0.010 | 0.45 | 0.07–2.98 | 0.409 | 0.57 | 0.26–1.22 | 0.147 |
Unknown | 0.71 | 0.61–0.82 | <.0001 | 2.38 | 2.09–2.69 | <.0001 | 2.59 | 1.97–3.40 | <.0001 | 2.92 | 2.04–4.20 | <.0001 | 2.05 | 1.49–2.82 | <.0001 |
Clinical nodal status (cN) | |||||||||||||||
cN0 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
cN1–3 | 0.96 | 0.88–1.05 | 0.410 | 2.47 | 2.26–2.69 | <.0001 | 1.49 | 1.19–1.86 | 0.001 | 1.59 | 1.18–2.14 | 0.003 | 0.82 | 0.61–1.23 | 0.423 |
Unknown | 1.02 | 0.77–1.36 | 0.880 | 1.42 | 1.09–1.86 | 0.010 | 1.46 | 0.79–2.70 | 0.223 | 1.43 | 0.62–3.28 | 0.400 | 0.87 | 0.33–2.03 | 0.667 |
ER, PR and HER2 status | |||||||||||||||
ER+ or PR+, and HER2− | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
ER+ or PR+, and HER2+ | 1.08 | 0.97–1.19 | 0.155 | 1.15 | 1.04–1.27 | 0.007 | 1.36 | 1.09–1.69 | 0.006 | 1.27 | 0.94–1.71 | 0.12 | 0.95 | 0.66–1.38 | 0.801 |
ER− and PR− and HER2− | 0.93 | 0.84–1.03 | 0.156 | 1.09 | 0.99–1.20 | 0.077 | 0.72 | 0.56–0.92 | 0.009 | 1.08 | 0.78–1.49 | 0.649 | 0.84 | 0.56–1.28 | 0.421 |
ER− and PR−and HER2+ | 1.10 | 0.96–1.27 | 0.183 | 1.60 | 1.39–1.85 | <.0001 | 1.18 | 0.83–1.67 | 0.351 | 2.13 | 1.40–3.25 | 0.001 | 0.45 | 0.20–1.03 | 0.057 |
Unknown | 0.88 | 0.72–1.07 | 0.195 | 1.11 | 0.94–1.31 | 0.206 | 0.84 | 0.56–1.27 | 0.413 | 1.52 | 0.91–2.56 | 0.114 | 2.31 | 1.61–3.32 | <.0001 |
Tumor grade | |||||||||||||||
1 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
2 | 0.91 | 0.84–0.97 | 0.008 | 1.21 | 1.13–1.30 | <.0001 | 1.62 | 1.34–1.95 | <.0001 | 1.91 | 1.44–2.52 | <.0001 | 0.72 | 0.59–0.88 | 0.001 |
3 | 0.78 | 0.71–0.85 | <.0001 | 1.17 | 1.07–1.27 | <.001 | 1.76 | 1.42–2.18 | <.0001 | 2.21 | 1.63–3.01 | <.0001 | 0.35 | 0.26–0.48 | <.0001 |
Unknown | 1.09 | 0.93–1.28 | 0.306 | 1.43 | 1.22–1.68 | <.0001 | 2.57 | 1.82–3.62 | <.0001 | 1.72 | 1.02–2.90 | 0.043 | 0.82 | 0.54–1.24 | 0.341 |
Multifocality | |||||||||||||||
No | 1 (ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
Yes | 2.62 | 2.43–2.82 | <.0001 | 4.70 | 4.34–5.09 | <.0001 | 2.88 | 2.39–3.47 | <.0001 | 4.41 | 3.47–5.60 | <.0001 | 0.82 | 0.63–1.06 | 0.129 |
Unknown | 0.38 | 0.25–0.57 | <.0001 | 1.77 | 1.33–2.34 | <.0001 | 3.15 | 1.18–8.45 | 0.023 | 1.72 | 0.40–7.37 | 0.466 | 0.82 | 0.37–1.84 | 0.634 |
Margin involvement | |||||||||||||||
No | |||||||||||||||
Yes | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 45.51 | 37.69–54.96 | <0.0001 | N/A | N/A | N/A |
Outcome characteristic | MRI use | Primary mastectomy | Margin involvement (more than focal) | Secondary mastectomy | Contralateral breast cancer | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OR | 95% CI |
P
| OR | 95% CI |
P
| OR | 95% CI |
P
| OR | 95% CI |
P
| OR | 95% CI |
P
| |
MRI | |||||||||||||||
No | N/A | N/A | N/A | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||
Yes | 0.86 | 0.76–0.99 | 0.030 | 0.59 | 0.44–0.79 | <.001 | 0.61 | 0.61 | 0.009 | 2.50 | 1.73–3.61 | <.0001 | |||
Year of incidence | |||||||||||||||
2011 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
2012 | 1.14 | 0.99–1.32 | 0.061 | 1.04 | 0.89–1.22 | 0.598 | 0.93 | 0.67–1.27 | 0.632 | 0.67 | 0.45–1.02 | 0.059 | 1.44 | 0.96–2.16 | 0.079 |
2013 | 1.30 | 1.13–1.51 | <.001 | 0.98 | 0.84–1.15 | 0.814 | 0.61 | 0.43–0.87 | 0.006 | 0.57 | 0.37–0.89 | 0.012 | 1.43 | 0.95–2.16 | 0.090 |
Age group (years) | |||||||||||||||
70+ | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
<50 | 4.01 | 3.31–4.87 | <.0001 | 0.70 | 0.57–0.86 | 0.001 | 1.38 | 0.87–2.19 | 0.173 | 2.14 | 1.20–3.82
| 0.010 | 0.85 | 0.52–1.38 | 0.498 |
50−69 | 2.71 | 2.37–3.10 | <.0001 | 0.50 | 0.43–0.58 | <.0001 | 1.09 | 0.77–1.54 | 0.640 | 1.22 | 0.78–1.92 | 0.378 | 0.65 | 0.44–0.95 | 0.025 |
Clinical tumor size (cT) | |||||||||||||||
cT1 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
cT2 | 1.83 | 1.60–2.09 | <.0001 | 3.95 | 3.43–4.55 | <.0001 | 1.74 | 1.26–2.40 | 0.001 | 2.17 | 1.44–3.25 | <.001 | 0.35 | 0.220.56 | <.0001 |
cT3–4 | 2.69 | 2.08–3.47 | <.0001 | 31.59 | 19.12–52.2 | <.0001 | 2.95 | 0.88–9.87 | 0.079 | 7.28 | 1.85–28.62 | 0.005 | 0.45 | 0.19–1.04 | 0.063 |
Unknown | 0.53 | 0.39–0.71 | <.0001 | 2.23 | 1.67–2.99 | <.0001 | 2.08 | 1.14–3.80 | 0.020 | 1.86 | 0.89–3.91 | 0.100 | 3.22 | 1.95–5.33 | <.0001 |
Clinical nodal status (cN) | |||||||||||||||
cN0 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
cN1–3 | 0.77 | 0.63–0.94 | 0.001 | 2.82 | 2.18–3.65 | <.0001 | 1.15 | 0.60–2.19 | 0.670 | 1.31 | 0.61–2.79 | 0.493 | 0.76 | 0.38–1.53 | 0.439 |
Unknown | 0.96 | 0.57–1.61 | 0.866 | 1.58 | 0.92–2.73 | 0.099 | 2.24 | 0.83–6.01 | 0.110 | 4.07 | 1.25–13.32 | 0.020 | 0.85 | 0.25–2.86 | 0.792 |
ER, PR and HER2 status | |||||||||||||||
ER+ or PR+, and HER2− | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
ER+ or PR+, and HER2+ | 0.75 | 0.56–1.02 | 0.067 | 1.49 | 1.06–2.09 | 0.020 | 0.67 | 0.28–1.61 | 0.372 | 0.87 | 0.29–2.60 | 0.804 | 1.31 | 0.56–3.05 | 0.536 |
ER− and PR− and HER2− | 0.52 | 0.34–0.79 | 0.002 | 1.19 | 0.74–1.92 | 0.476 | 1.17 | 0.43–3.18 | 0.762 | 2.50 | 0.77–8.13 | 0.127 | 0.42 | 0.06–3.09 | 0.395 |
ER− and PR− and HER2+ | 1.35 | 0.62–2.98 | 0.451 | 1.66 | 0.71–3.92 | 0.245 | 0.70 | 0.08–6.06 | 0.748 | 1.51 | 0.15–15.3 | 0.727 | 4.02 | 0.79–20.35 | 0.093 |
Unknown | 0.36 | 0.25–0.53 | <.0001 | 1.70 | 1.18–2.44 | 0.004 | 0.49 | 0.18–1.39 | 0.183 | 0.60 | 0.17–2.07 | 0.414 | 1.98 | 1.01–3.90 | 0.047 |
Tumor grade | |||||||||||||||
1 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
2 | 0.81 | 0.69–0.95 | 0.011 | 1.33 | 1.12–1.57 | 0.001 | 0.96 | 0.68–1.37 | 0.833 | 0.94 | 0.61–1.47 | 0.794 | 0.70 | 0.48–1.04 | 0.077 |
3 | 0.60 | 0.47–0.76 | <.0001 | 1.39 | 1.06–1.81 | 0.016 | 1.55 | 0.90–2.65 | 0.113 | 1.11 | 0.56–2.22 | 0.763 | 0.36 | 0.15–0.87 | 0.024 |
Unknown | 0.97 | 0.72–1.32 | 0.860 | 1.15 | 0.83–1.58 | 0.400 | 0.99 | 0.50–1.94 | 0.964 | 0.66 | 0.27–1.59 | 0.351 | 0.83 | 0.43–1.63 | 0.597 |
Multifocality | |||||||||||||||
No | 1 (ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | |||||||||||
Yes | 1.59 | 1.38–1.82 | <.0001 | 3.81 | 3.26–4.45 | <.0001 | 2.39 | 1.71–3.34 | <.0001 | 6.74 | 4.50–10.08 | <.0001 | 1.48 | 1.04–2.09 | 0.029 |
Unknown | 0.40 | 0.21–0.76 | 0.006 | 0.66 | 0.37–1.18 | 0.162 | 5.00 | 1.42–17.53 | 0.012 | 13.79 | 2.94–64.6 | 0.001 | 1.29 | 0.36–4.56 | 0.695 |
Margin involvement | |||||||||||||||
No | 1 (Ref) | ||||||||||||||
Yes | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 34.77 | 23.84–50.71 | <0.0001 | N/A | N/A | N/A |